CellResearchCorp

Executive Summary

CellResearchCorp is a Singapore-based regenerative medicine company founded in 2002 that specializes in isolating and commercializing epithelial and mesenchymal stem cells derived from the umbilical cord lining membrane. The company has developed proprietary banking protocols and maintains a global cord registry to supply high-quality stem cells for clinical applications. Its lead therapeutic program is a US FDA-registered Phase 1 wound-healing trial targeting chronic wounds, leveraging its unique cord-lining stem cell platform. In parallel, CellResearchCorp markets the CALECIM® cosmeceutical line for skin rejuvenation, generating revenue and validating its cell-based technology in a commercial setting. The company is privately held with an estimated 50–200 employees and operates at an early clinical stage (Phase 1). Its dual focus on clinical-stage therapies and consumer products provides a diversified risk profile, though progress in the FDA trial and product adoption will be key to near-term valuation.

Upcoming Catalysts (preview)

• Q2 2026Top-line results from Phase 1 wound-healing trial60% success
• Q3 2026Launch of new CALECIM products in Asian markets70% success
• TBDStrategic licensing partnership for cord-lining stem cell platform30% success